SCHEMBL15052622

SCHEMBL15052622

COc1ccc(/C=C/C(=O)NN)cc1OC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 1/20 0.69
KDM4E B2RXH2 5/20 0.67
ALDH1A1 P00352 5/20 0.67
HPGD P15428 4/20 0.67
SMN1; SMN2 Q16637 3/20 0.67
MAPK1 P28482 2/20 0.67
HSD17B10 Q99714 2/20 0.67
ALOX15 P16050 1/20 0.67
KMT2A Q03164 7/20 0.66
MEN1 O00255 6/20 0.66
RAB9A P51151 3/20 0.66
NPC1 O15118 2/20 0.66
STAT1 P42224 1/20 0.66
ABCG2 Q9UNQ0 2/20 0.63
CYP1A2 P05177 2/20 0.61
CA1 P00915 2/20 0.61
CA2 P00918 2/20 0.61
CA12 O43570 1/20 0.61
CA9 Q16790 1/20 0.61
TP53 P04637 3/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15052623 1.00 NFE2L2 (0.69) NFE2L2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL29096325 0.89 ALDH1A1 (0.68) NFE2L2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL459772 0.88 BCHE (0.66) KDM4EALDH1A1HPGDMAPK1ALOX15
SCHEMBL29204551 0.88 KDM1A (0.71) NFE2L2KDM4EALDH1A1HPGDMAPK1
SCHEMBL459773 0.88 BCHE (0.66) KDM4EALDH1A1HPGDMAPK1ALOX15
SCHEMBL29235271 0.88 KDM1A (0.71) NFE2L2KDM4EALDH1A1HPGDMAPK1
SCHEMBL31482423 0.87 NFE2L2 (0.73) NFE2L2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL9059283 0.87 APP (0.69) NFE2L2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL9059285 0.87 APP (0.69) NFE2L2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL10562864 0.86 HDAC1 (0.72) NFE2L2KDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853276-B2 Guanidine derivatives in cinnamic series PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) 2014-10-07 US disclosed
EP-2614046-B1 NOVEL GUANIDINE DERIVATIVES IN THE CINNAMIC SERIES PROD CHIM AUXILIAIRES ET DE SYNTHESE (FR) 2014-08-20 EP disclosed
US-20130165507-A1 NEW GUANIDINE DERIVATIVES IN CINNAMIC SERIES PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165507-A1 NEW GUANIDINE DERIVATIVES IN CINNAMIC SERIES GMPS, UNG, AGER NFE2L2 353/4885KDM4E 1037/4885ALDH1A1 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.